RU2811246C1 - Viamin therapy for recipient cows before embryo transplantation - Google Patents

Abstract

FIELD: veterinary medicine.

SUBSTANCE: invention relates to means for increasing the percentage of embryo engraftment in recipient cows. A method of vitamin therapy for recipient cows has been proposed, which includes injecting Eleovit intramuscularly in a dose of 5 ml twice with an interval of 14 days during preparation for embryo transfer.

EFFECT: use of the proposed method improves the survival rate of embryos in recipient cows.

1 cl, 2 tbl

Description

The invention relates to veterinary medicine, in particular to means for increasing the percentage of embryo engraftment in recipient cows.

When preparing recipient cows, special attention should be paid to nutritional factors of infertility, the main of which is vitamin nutrition.

Currently, there are traditional methods of feeding cows with vitamins, in particular enriching feed with vitamin premixes, which have a number of disadvantages.

There is a known method for normalizing the immunobiochemical homeostasis of cows in the prenatal and postpartum periods (patent RU 2252767, published on May 27, 2005). According to the invention, cows 20-25 days before calving are administered a single intramuscular injection of 0.5% sodium selenite solution in a dose of 10 ml. Twice before and twice after calving with an interval of 10 days - tetravit in a dose of 10 ml containing 1 ml of 50,000 IU of vitamin A, 25,000 IU of vitamin D, 20 mg of vitamin E and 5 mg of vitamin.

A premix for lactating cows is known (patent RU 2145479, published on February 20, 2000), containing mineral components, vitamins and irradiated hydrolytic yeast used as vitamin D.

The disadvantage of this invention is the absence of such vital microelements as iron and vitamins A, E, B ₁ , B ₅ , B ₇ . The proposed premix is not designed for highly productive cows whose average daily milk yield is 20 kilograms or more. The hydrolytic yeast used is not able to influence the stabilization of rumen digestion, because all useful living cultures are irradiated and inactive.

There is a known method of using a mineral-vitamin premix to stabilize the physiological state of cows (patent RU 2303367, published on July 27, 2007). The premix contains manganese, zinc, copper, phosphorus, vermiculite and vitamin A and is formulated for different phases of lactation of dairy cows.

The disadvantage of this feed additive is that it does not take into account the physiological norms of the need for individual microelements (manganese, zinc). In addition, the food supply in the regions of Russia is not taken into account.

A method for the prevention of postpartum diseases in cows is presented in (patent RU 2201221, published on March 27, 2003). It consists in the fact that dry cows are sequentially injected intramuscularly with 10 ml of a 0.5% selenium solution twice 40-50 days before calving and a month after the first injection, with the simultaneous introduction into the diet of premix P 52-1, chalk, sulfur and iodine.

The disadvantage of the proposed method is the difficulty of justifying the result obtained, since one drug is administered intramuscularly, and the premix is given along with the feed.

There is a known method for reducing early embryonic mortality in cattle, which consists in the fact that 5-8 days after insemination, cows are given a single dose of 10 mcg of buserelin, while fertility increased by 6-12% (Ryan, D.P. Pregnancy rates in dairy cows following the administration of a GnRH analogue at the time of artificial insemination or at midcycle post insemination/ D.P. Ryan, E. Kopel, M.P. Boland M.P.// Theriogenology. - 1991. - V.36. - No. 3. - pp.367-377) . The advantage of this method is its ease of use; it allows you to enhance the functional activity of the corpus luteum of pregnancy by increasing the secretion of luteinizing hormone by the pituitary gland and increasing the endogenous level of progesterone. However, this method is not able to regulate metabolic processes in the endometrium, which in some cases also leads to embryonic mortality due to insufficient provision of nutrients to the embryo before and during implantation. In some cases, the mother's immune system perceives the embryo as an antigen, which ultimately also leads to its death. The above method is also not able to influence the immune status of the maternal body.

As the closest analogue, a method was chosen to improve the reproductive function of animals, in particular cows (patent RU 2230524, published on June 20, 2004), carried out by introducing a mineral component and vitamins into the animal’s body. As a mineral component, a prolonged form of selenopyran is used based on the content of 300 mg of selenopyran. The specified mineral component is administered to dry cows once parenterally 15 days before calving, and simultaneously with the injection of selenopyran, the cows are given a single dose of fat-soluble vitamins D - 500,000 IU, E - 1000 IU, A - 2,000,000 IU per head with feed.

The disadvantage of the proposed method is the difficulty of analyzing the results obtained, since one drug is administered parenterally, and the remaining vitamins are given with food.

The technical result of the present invention is to increase the percentage of embryo engraftment in recipient cows.

The technical result is achieved by the fact that during preparation for embryo transfer, recipient cows are intramuscularly injected with the drug Eleovit (manufactured by NPK Askont+ LLC, Moscow region) in a dose of 5 ml twice with an interval of 14 days.

Dosage form: solution for injection. Eleovit in 1 ml contains as active ingredients: vitamin A - 10000 IU, vitamin D ₃ - 2000 IU, vitamin E - 10 mg, vitamin K ₃ - 1 mg, vitamin B ₁ - 10 mg, vitamin B ₂ - 4 mg, vitamin B ₆ – 3 mg, cyanocobalamin – 10 mcg, biotin – 10 mcg, nicotinamide – 30 mg, pantothenic acid – 20 mg, folic acid – 0.2 mg and excipients: lactoalbumin protein hydrolysate – 0.2 mg, glucose – 50 mg, water for injection - up to 1 ml. In appearance, the drug is an oily liquid (opalescence is allowed) from light yellow to light brown in color with a specific odor.

The multivitamins included in Eleovit have a synergistic effect. Vitamin A regulates the function and regeneration of epithelial tissues, thereby increasing the protective function of the animal body. Vitamin D ₃ is involved in the metabolism of calcium and phosphorus and has an antirachitic effect. Vitamin E, being a strong antioxidant, regulates redox processes and enhances the effect of vitamins A and D ₃ . B vitamins play an important role in normalizing metabolism and regulating nervous processes.

In terms of the degree of impact on the body, Eleovit is classified as a low-hazard substance (hazard class 4 according to GOST 12.1.007).

The method is carried out as follows

The preparatory period for recipient cows lasted for a month. After a clinical examination, the animals were divided into 2 groups - experimental and control, 6 animals in each. An experimental group of cows received a course of vitamin therapy with Eleovit, intramuscularly at a dose of 5 ml twice with an interval of 14 days. The control group did not receive a course of vitamin therapy.

Before vitamin therapy and after completing the course of Eleovit, a clinical examination of animals was carried out (Table 1).

Table 1. Physiological parameters of cows

Group Temperature, ºС Pulse, beats/min Breathe, breathe. dpm Standard interval 37.5‒39.0 50‒80 15‒30 Before the course of drug administration Test 38.8±0.23 88.5±1.09 41.0±2.04 Experienced 38.6 ±0.18 78.5±0.93** 29.3±1.19** After a course of drug administration Test 38.4±0.42 79.0±1.33 30.5±1.62 Experienced 38.5 ±0.44 67.6±0.83** 26.0±2.38** The differences are statistically significant compared to the control: **P<0.01; ***P<0.001.

A clinical examination of recipient cows before the start of the experiment showed that the body temperature of the animals in both groups was within the physiological norm, but in the control group the pulse and the number of respiratory movements were slightly higher than normal. After the course of drug administration (end of the experiment), physiological parameters in the experimental and control groups were within normal limits.

Embryos were implanted into recipient cows in both groups into the uterine horn on the side in which the corpus luteum was well developed in the ovary.

After embryo transfer, the recipient cows of the experimental and control groups were fed and kept under normal conditions, avoiding stress. The effectiveness of the method was determined by calculating the number of recipient cows that underwent embryo transfer according to the level of embryo survival. Pregnancy was determined using a rectal ultrasound scanner on day 28. The results of the experiment are shown in Table 2.

Table 2. Ultrasound diagnostic results

Index Group of animals (recipient cows) Test Experienced Number of embryo transfers, n 6 6 Number of pregnant recipients, goal - % 2/33.3 4/66.6

The number of pregnant recipient cows in the experimental group was 66.6%, which is 33.3% more than in the control group.

As a result of vitamin therapy with Eleovit during the preparation of recipient cows for embryo transfer, the number of pregnant recipient cows increased significantly.

Claims (1)

Vitamin therapy for recipient cows before embryo transplantation, characterized in that during preparation for embryo transfer, recipient cows are intramuscularly administered the drug Eleovit in a dose of 5 ml twice with an interval of 14 days.